SCHEMBL3782102

SCHEMBL3782102

Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 6/20 0.57
PIK3CA P42336 6/20 0.57
PIK3CB P42338 6/20 0.57
PIK3CG P48736 6/20 0.57
PRKDC P78527 6/20 0.57
KDM4E B2RXH2 5/20 0.49
SRC P12931 5/20 0.49
HPGD P15428 3/20 0.49
ALDH1A1 P00352 3/20 0.49
YES1 P07947 3/20 0.49
FYN P06241 3/20 0.49
RIPK2 O43353 2/20 0.49
LYN P07948 2/20 0.49
ABL1 P00519 2/20 0.49
EGFR P00533 2/20 0.49
KDR P35968 2/20 0.49
MTOR P42345 2/20 0.49
PLK4 O00444 1/20 0.49
ROCK2 O75116 1/20 0.49
PRKD3 O94806 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12713498 0.92 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL30387175 0.87 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL5065122 0.84 PIK3CD (0.57) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL3715031 0.84 SRC (0.57) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL15613778 0.84 PIK3CD (0.42) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL11325 0.84 PIK3CG (0.49) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL408618 0.83 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL149528 0.83 KDR (0.52) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL5088174 0.83 PIK3CD (0.60) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20793716 0.83 ADK (0.51) KDRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230111917-A1 KINASE ANTAGONISTS UNIV CALIFORNIA (US) 2023-04-13 US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 US disclosed
EP-2590982-B1 PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT THE WALTER AND ELIZA HALL INST OF MEDICAL RES (AU) 2017-08-23 EP disclosed
WO-2017043550-A1 CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-03-16 WO disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 US disclosed
US-8962830-B2 Protein kinase inhibitors and methods of treatment THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2015-02-24 US disclosed
US-20130184274-A1 Protein Kinase Inhibitors and Methods of Treatment THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2013-07-18 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
WO-2010033906-A2 EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184274-A1 Protein Kinase Inhibitors and Methods of Treatment PRKDC, PRKACA, PRKX PIK3CD 164/4885PIK3CA 69/4885PIK3CB 153/4885
US-20230111917-A1 KINASE ANTAGONISTS MTOR, RPS6KA3, AKT3 PIK3CD 12/4885PIK3CA 4/4885PIK3CB 21/4885
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B PIK3CD 2217/4885PIK3CA 3103/4885PIK3CB 1964/4885
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK PIK3CD 357/4885PIK3CA 414/4885PIK3CB 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.